Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332036 | 0.89 | SLC6A3 (0.42) | SLC6A3SLC6A4SLC6A2CYP2D6KCNH2 | |
| SCHEMBL2157360 | 0.87 | SLC6A4 (0.48) | SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL2157274 | 0.86 | SLC6A4 (0.48) | SLC6A3SLC6A4KCNH2 | |
| SCHEMBL1333967 | 0.79 | HTR1A (0.44) | SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL2158456 | 0.76 | KCNA5 (0.45) | — | |
| SCHEMBL7302397 | 0.75 | SLC6A3 (0.68) | SLC6A3 | |
| Hydrochloric Acid SCHEMBL7321944 | 0.74 | SLC6A3 (0.67) | SLC6A3 | |
| SCHEMBL5656404 | 0.74 | NPC1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL7321403 | 0.72 | KCNH2 (0.73) | KCNH2 | |
| SCHEMBL3784355 | 0.72 | SIGMAR1 (0.44) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | SLC6A3 338/4885SLC6A4 424/4885SLC6A2 413/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | SLC6A3 294/4885SLC6A4 497/4885SLC6A2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.